Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

NCT00433381 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

NIH

Sponsor class

Conditions

Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Irinotecan Hydrochloride
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]